[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session .

Keyword Index: M

[ 0 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ]
Macrophage
Magnetic Resonance Imaging
Maintenance
Malaria
Male
Malignancy
Malignant Lymphoma
MALT Lymphoma
MAP Kinase
Marginal Zone
Marrow
Marrow Failure
Mast Cell
Mastocytosis
Mcl-1
MCP-1
MDR1
Medical Patients
79
Megakaryocyte
Megakaryocyte Differentiation
Megakaryopoiesis
Meis1
120
MEK
Melphalan
Memory T Cells
Menorrhagia
Mesenchymal Stem Cell
Mesenchymal Stromal Cell
Meta-Analysis
Metabolic Syndrome
Metastasis
Methotrexate
MGUS
MHC
489
MHC Class I
Microarray Analysis
Microparticles
Microvesicles
Migration
Minimal Residual Disease (MRD)
Minor Histocompatibility Antigen
Mismatched
956
Mitochondria
Mitochondrial DNA
Mixed Lineage Leukemia
MMP
Mobilization
Molecular
Molecular Cytogenetics
Molecular Markers
Molecular Remission
Molecular Response
Monitor
Monoclonal Antibody
Monoclonal Gammopathy
Monocyte
Mortality
MRI
Mucositis
Multidrug Resistance
Multiple Sclerosis
962
Multi-Step
859
Murine Models
Mutagenesis
Mutation Status
Mycophenolate mofetil (MMF, Cellcept)
Mycosis fungoides
Myeloid
Myeloid Differentiation
Myeloid Leukemia
Myeloid Malignancies
Myelopoiesis
Myeloproliferative Disorder
Myelosuppression
Myocardial Infarction
[ 0 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ]